Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines

Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines

The molecular heterogeneity of cancer calls for individualized therapies to become the standard of care. The development of new therapeutic agents needs to include integrative translational research as early as possible. Target-specific compounds require specific diagnostic biomarker support. Tailor...

Full description

Bibliographic Details
Main Authors: Julia eEschenbrenner, Sebastian eWinsel, Stefanie eHammer, Anette eSommer, Kevin eMittelstaedt, Michael eDrosch, Ulrich eKlar, Christoph eSachse, Michael eHannus, Monika eSeidel, Bertram eWeiss, Claudia eMerz, Gerhard eSiemeister, Jens eHoffmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-11-01
Series:Frontiers in Oncology
Subjects:
breast cancer models
epothilone
KIF2C (MCAK)
microtubule-stabilizing agent
RNAi drug modifier screen
sagopilone
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00044/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00044/full

Similar Items